Literature DB >> 14501943

Anti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia: increased mortality in the absence of liver injury.

Thomas A Moore1, Helen Y Lau, Anna L Cogen, Christine L Monteleon, Theodore J Standiford.   

Abstract

Klebsiella pneumoniae is a leading cause of gram-negative bacterial pneumonia, often resulting in bacteremia concurrent with the localized pulmonary infection. The beneficial role of tumor necrosis factor (TNF)-alpha during pulmonary infection has been well documented; however, consequences of TNF-alpha production during systemic bacterial infection are controversial. A murine model of K. pneumoniae was developed to address this important issue. Liver-associated TNF-alpha mRNA was induced within 30 min after intravenous bacterial inoculation and remained elevated through 6 h before returning to near-baseline at 24 h postinfection. Intravenous K. pneumoniae infection induced liver cellular injury that was completely ablated when mice were pretreated with a neutralizing anti-TNF-alpha antibody. Interestingly, this reduction in liver injury failed to translate into improved survival. Mice receiving anti-TNF-alpha continued to succumb to the infection even out to day 10 postinfection. Bacterial clearance after TNF-alpha neutralization was significantly impaired at later time points during infection. Correlating with impaired bacterial clearance was diminished production of liver-associated MIP-2, MIP-1alpha, MCP-1, and interferon-gamma. Further evidence of diminished antibacterial immune responses was noted when the activational status of splenic natural killer cells in anti-TNF-alpha-treated mice was examined 24 h postinfection. Natural killer cells displayed decreased CD69 expression. Combined, these data indicate that the beneficial effects of TNF-alpha during systemic K. pneumoniae infection outweigh the detrimental effects of TNF-alpha-mediated hepatocyte cellular injury. Anti-TNF-alpha therapy, although preventing liver injury during blood-borne bacterial infection, results in a dampened anti-bacterial host response, resulting in decreased bacterial clearance and overall survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501943     DOI: 10.1097/01.shk.0000087203.34916.45

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  12 in total

Review 1.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

2.  Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria.

Authors:  Jill R Schurr; Erana Young; Pat Byrne; Chad Steele; Judd E Shellito; Jay K Kolls
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Modeling Klebsiella pneumoniae pathogenesis by infection of the wax moth Galleria mellonella.

Authors:  José Luis Insua; Enrique Llobet; David Moranta; Camino Pérez-Gutiérrez; Anna Tomás; Junkal Garmendia; José A Bengoechea
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

4.  Beta2-microglobulin-dependent bacterial clearance and survival during murine Klebsiella pneumoniae bacteremia.

Authors:  Anna L Cogen; Thomas A Moore
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

5.  M-CSF Mediates Host Defense during Bacterial Pneumonia by Promoting the Survival of Lung and Liver Mononuclear Phagocytes.

Authors:  Alexandra Bettina; Zhimin Zhang; Kathryn Michels; R Elaine Cagnina; Isaah S Vincent; Marie D Burdick; Alexandra Kadl; Borna Mehrad
Journal:  J Immunol       Date:  2016-05-04       Impact factor: 5.422

Review 6.  Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock.

Authors:  Ineke Vanlaere; Claude Libert
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

7.  Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases.

Authors:  S Aslanidis; T Vassiliadis; A Pyrpasopoulou; I Douloumpakas; C Zamboulis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 3.650

8.  The safety of etanercept for the treatment of plaque psoriasis.

Authors:  Kim A Papp
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

9.  HLA-DR expression, cytokines and bioactive lipids in sepsis.

Authors:  Undurti Das
Journal:  Arch Med Sci       Date:  2014-05-13       Impact factor: 3.318

10.  Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.

Authors:  Franco Capsoni; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Francesca Minonzio; Paola Bonara; Andrea Doria; Mario Carrabba
Journal:  Arthritis Res Ther       Date:  2005-01-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.